Skip to main content
SpringerLink
Log in

Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease

  • Pediatric Gastroenterology (S Orenstein and S Khan, Section Editors)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease in both adults and children. In this article, we review recent developments in the screening, diagnosis, and treatment of pediatric NAFLD.

Recent Findings

Although alanine aminotransferase (ALT) remains the best screening test for NAFLD in children, and liver biopsy is still required for the diagnosis of nonalcoholic steatohepatitis (NASH), other noninvasive biomarker/imaging studies (MRI-PDFF and VCTE) have emerged as diagnostic methods for pediatric NAFLD. Two large clinical therapeutic trials testing vitamin E, metformin, and cysteamine in pediatric NAFLD yielded mostly inconclusive results. Bariatric surgery has begun to be used in adolescents with severe obesity. An adult phase 2 study using obeticholic acid (OCA) to treat NASH patients with fibrosis showed some positive results. As we continue to await the first FDA-approved therapeutic agent for NASH, lifestyle change remains the main modality of treatment.

Summary

Newer diagnostic and treatment modalities for pediatric NAFLD continue to be in development under FDA guidance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.

    Article  PubMed  Google Scholar 

  2. Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease? BMJ. 2011;343:d3897.

    Article  PubMed  Google Scholar 

  3. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–90.

    Article  CAS  PubMed  Google Scholar 

  4. Yu EL, Golshan S, Harlow KE, Angeles JE, Durelle J, Goyal NP, et al. Prevalence of nonalcoholic fatty liver disease in children with obesity. J Pediatr. 2019;207:64–70.

    Article  PubMed  Google Scholar 

  5. Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology. 2016;64(1):19–22.

    Article  PubMed  Google Scholar 

  6. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.

    Article  PubMed  Google Scholar 

  7. Welsh JA, Karpen S, Von MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. J Pediatr. 2013;162(3):496–500.e1.

    Article  PubMed  Google Scholar 

  8. Riley MR, Bass NM, Rosenthal P, Merriman RB. Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. J Pediatr. 2005;147(6):839–42.

    Article  PubMed  Google Scholar 

  9. Barlow SE. Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(suppl 4):S164–92.

    Article  PubMed  Google Scholar 

  10. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319–34.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Schwimmer JB, Newton KP, Awai HI, Choi LJ, Garcia MA, Ellis LL, et al. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38(10):1267–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Awai HI, Newton KP, Sirlin CB, Behling C, Schwimmer JB. Evidence and recommendations for imaging liver fat in children, based on systemic review. Clin Gastroenterol Hepatol. 2014;12(5):765–73.

    Article  PubMed  Google Scholar 

  13. Schwimmer JB, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology. 2015;61(6):1887–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011;21(1):87–97.

    Article  PubMed  Google Scholar 

  15. Loomba R, Sirlin CB, Schwimmer JB, Lavine J. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009;50(4):1282–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Vuppalanchi R, Gould RJ, Wilson LA, Unalp-Arida A, Cummings OW, Chalasani N, et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int. 2012;6(1):379–85.

    Article  PubMed  Google Scholar 

  17. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork N, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology. 2009;136(5):1585–92.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Loomba R, Chalasani N. The hierarchical model of NAFLD: prognostic significance of histologic features in NASH. Gastroenterology. 2015;149(2):278–81.

    Article  PubMed  Google Scholar 

  19. Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic grades and nonalcoholic fatty liver disease. Radiology. 2015;274(2):416–25.

    Article  PubMed  Google Scholar 

  20. Middleton MS, Van Natta ML, Heba ER, Alazraki A, Trout AT. Masand P Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology. 2018;67(3):858–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Peitrobattista A, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008;48(2):442–8.

    Article  CAS  PubMed  Google Scholar 

  22. Xanthakos SA, Podberesky DJ, Serai SD, Miles L, King EC, Balistreri WF, et al. Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease. J Pediatr. 2014;164(1):186–8.

    Article  PubMed  Google Scholar 

  23. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48(1):119–28.

  24. •• Schwimmer JB, Ugalde-Nicalo P, Welsh JA, Angeles JE, Cordero M, Harlow, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial. JAMA. 2019;321(3):256–65. This study showed the provision of a diet low in free sugar result in significant improvement of hepatic steatosis in adolescents with NAFLD.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Dohil R, Cabrera BL SS, Wang T, Durelle J, Duke KB, et al. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33(9):1036–44.

    Article  CAS  PubMed  Google Scholar 

  27. Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, et al. In children with nonalcoholic fatty liver disease, cysteamine bitatrate delayed release improves liver enzymes but does not reduced disease activity scores. Gastroenterology. 2016;151(6):1141–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Lin CH, Kohli R. Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease. Clin Transl Gastroenterol. 2018;9(6):164.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(3):574–82.

    Article  CAS  PubMed  Google Scholar 

  30. •• Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman A, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicenter, randomized, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–96. The study showed obeticholic acid significantly improved fibrosis and key component of NASH disease activity among adult patients with NASH.

    Article  CAS  PubMed  Google Scholar 

  31. Eslam M, Alvani R, Shiha G. Obeticholic acid: towards first approval for NASH. Lancet. 2019;394(10215):2131–3.

    Article  PubMed  Google Scholar 

  32. Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Helmrath MA, Brandt ML, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016;374(2):113–23.

    Article  CAS  PubMed  Google Scholar 

  33. Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149(2):379–88.

    Article  PubMed  Google Scholar 

  34. Manco M, Mosca A, De Peppo F, Caccamo R, Gutrera R, Cutrera R, et al. The benefit of sleeve gastrectomy in obese adolescents on nonalcoholic steatohepatitis and hepatic fibrosis. J Pediatr. 2017;180:31–7.

    Article  PubMed  Google Scholar 

  35. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–78.

    Article  PubMed  Google Scholar 

  36. US Department of Health and Human Services. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment. Guidance for industry. December 2018. https://www.fda.gov/media/119044/download (accessed June 30, 2020).

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital Los Angeles, and the Department of Pediatrics, Keck School of Medicine, University of Southern California, 4650 Sunset Boulevard, Mail Stop 78, Los Angeles, CA, 90027, USA

    Chuan-Hao Lin & Rohit Kohli

Authors
  1. Chuan-Hao Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rohit Kohli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chuan-Hao Lin.

Ethics declarations

Conflict of Interest

RK served as a consultant for Intercept Pharmaceuticals. CHL: none.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Topical Collection on Pediatric Gastroenterology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, CH., Kohli, R. Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease. Curr Gastroenterol Rep 22, 52 (2020). https://doi.org/10.1007/s11894-020-00786-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-020-00786-y

Keywords

Search

Navigation